~~<i id='12BDE60A8B'><strike id='12BDE60A8B'><tt id='12BDE60A8B'><pre id='12BDE60A8B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

author：knowledge 2025-10-01 11:47:22 - browse：24922

Adam's take main illustration — Molly Ferguson/STAT

I was wrong about Geron.

For years, I’ve believed — and declared publicly — that Geron’s effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved, I said.

On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat’s favor, concluding the drug’s benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome. The strong endorsement makes an FDA approval highly likely. The decision is expected on or before June 16.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Readout LOUD podcast: Venture capital turmoil, obesity drug competition

hotspot

knowledge

Wikipedia

hotspot

focus

Wikipedia

DarronCummings/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne

WSS

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Change Healthcare cyberattack prompts Medicare loan program

Change Healthcare payments predicted restored March 15

CDC marks new Covid

NEJM study link tiny plastics in blood vessels to heart problems

leisure time

leisure time

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Judge rejects Trump's request to move Stormy Daniels hush

Malaria cases in Florida and Texas: Here’s what you need to know

NEJM study link tiny plastics in blood vessels to heart problems

Sports medicine is finally prioritizing gender equality

Former medical device CEO who sold dummy, plastic parts convicted of fraud

How to save PrEP access — and even expand it

7 more heat

Cancer drug shortages should be causing more outrage

I learned firsthand about improving diversity in clinical trials

knowledge

The problem with charging patients to message their doctors

Indian pharmaceutical industry in denial over drug

First medicine developed to treat MASH expected to be approved soon

How to bring more disabled researchers into academia

Hospitals struggle to profit from CAR

Air quality improving but still lags in Black, Hispanic communities

Wikipedia

hotspot

focus

Wikipedia